RxDoctor Payments Data

Tonna Coleman

Medical · Columbia, SCNPI 1720367170

Payments from drug & device makers

$1,206in general payments, 2019–2025

Across 51 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$447
  • Novo Nordisk$173
  • Medtronic$80
  • Merz North America, Inc.$77
  • Teleflex LLC$71
  • AstraZeneca$70
  • plus $289 from 12 others

What the payments were for

  • Food & beverage$1,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,206 in reported general payments places this provider in the 55th percentile of 384 medical providers in South Carolina.

See all medical providers in South Carolina

Medicare billing

Part B allowed, 2024
$19,221
Medicare patients
77
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$48,656
FarxigaDapagliflozin Propanediol22$19,344
JardianceEmpagliflozin18$18,797
MyrbetriqMirabegron15$9,495
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,254
Atorvastatin Calcium159$1,642
Rosuvastatin Calcium56$1,292
Omeprazole46$1,122
Amlodipine Besylate133$1,060
Olmesartan Medoxomil34$970
Gabapentin59$847
Losartan Potassium64$678
Levothyroxine Sodium47$661
Fluticasone Propionate56$656
SynthroidLevothyroxine Sodium13$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$447$48,65649 claims
AstraZenecaFarxiga$70$19,34422 claims
AbbVieSynthroid$22$54213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 384 medical providers in South Carolina.

Other medical in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →